Several other vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have obtained emergency approvals in many countries after demonstrating their effectiveness in preventing severe illness and hospitalizations due to coronavirus disease 2019 (COVID-19) up to 20 weeks after vaccination.
Study: SARS-CoV-2 Spike S1-specific IgG kinetic profiles after mRNA vaccination compared to vector in the general Dutch population. Image credit: angellodeco/Shutterstock. com
In the Netherlands, 4 vaccines have been included in the national vaccination programme, two of which are messenger ribonucleic acid (mRNA) generation (Comirnaty and Spikevax), while the other two are vector (Vaxzevria and Janssen).
In particular, mRNA-based vaccines use lipid nanoparticles to deliver peak-coding mRNA, while vector-based vaccines use adenoviruses to deliver peak-coding deoxyribonucleic acid (DNA) to induce host cells to produce neutralizing antibodies opposite to the spike viral protein.
Several reports have independently described the induction of spike express antibodies through existing COVID-19 vaccines. However, most of these effects were received in express groups, such as other immunocompromised people or health care workers. As a result, head-to-head comparisons of mRNA and vector-based vaccines in the general population are rare, as are comparisons comparing those 4 vaccines simultaneously.
The PIENTER-Corona (PiCo) test is a Dutch national efficacy comparison test, in which participants aged 18 years and older who received one or two doses of Comirnaty, Spikevax, Vaxzevria or Janssen are compared for SARS-CoV-2 peak S1 – expressing the antibody concentrations (S1) induced by each type of vaccine. A recent report on the first effects of the PiCo study published on the medRxiv* preprint server.
In the study provided, researchers compared post-vaccination immunoglobulin G (IgG) (S1) antibodies with samples of mRNA-based (Comirnaty, Spikevax) or vector-based (Janssen, Vaxzevria) vaccines from a Dutch national cohort.
Knowledge was collected in February and June 2021 following the launch of the Dutch national COVID-19 vaccination crusade from public physical fitness knowledge bases. Data availability was decided through the vaccine rollout and prioritization of aging populations in the crusade.
For other people aged 18 to 64 years, data were to be available up to two months after each dose of the 4 vaccines for an overall total of 2412 more people. For the Comirnaty vaccine, data had to be taken in SARS-Americans with no experience with CoV-2 aged 18 to 91 years up to 4 months after the current dose consistent with 196 other people. S1 antibody concentrations were measured and expressed in ml binding antibody sets (BAU/ml)
The median vaccination period between the two doses was 77 days for Vaxzevria, 35 days, and 33 days for Comirnaty and Spikevax. -based on vaccines. After accumulation of antibody concentrations after the current dose, an immediate initial minimum may be observed until it nevertheless stabilizes.
Spike S1 immunoglobulin G (IgG) kinetics after COVID-19 vaccination through vaccine number and logo in older adults aged 18 to 64 years who had not received SARS-CoV-2. The dashed horizontal line represents the threshold of HIV status. Janssen’s knowledge is duplicated on either panel to be consistent with direct comparison with other vaccine logos after a dose and a full vaccination schedule. For comparison, IgG concentrations after a positive SARS-CoV-2 PCR or antigen test in unvaccinated participants are presented along with vaccine responses; Knowledge is duplicated in both panels (for details, see Additional Table 3). The 95% compatibility and confidence bands are presented from a generalized additive model, penalized splines, with only the time elapsed since the dose in days as the explanatory variable. . For the effects of multivariate models, see Companion Table 1. BAU/mL: binding antibody assemblies consistent with mL; IgG: immunoglobulin G.
For vector-based vaccines, the slowest accumulation in IgG S1 grades stabilized with no obvious decrease. Between fourteen days and two months after completion of the vaccination schedule or a positive SARS-CoV-2 test, the median IgG grades were 2,799 BAU/mL for Spikevax, 2408 BAU/mL for Comirnaty, 313 BAU/mL for Vaxzevria, 64 BAU/mL for Janssen, and 91 BAU/mL for participants not vaccinated with SARS-CoV-2.
The 3 who did not respond to Spikevax, Comirnaty and Vaxzevria were at the highest threat of comorbidities. In Janssen recipients, IgG S1 levels exceeded 77 BAU/mL without comorbidity for none of those who did not respond twenty-eight days after vaccination. Regression effects showed that age, sex, and presence of comorbidities contributed particularly to IgG S1 concentrations; However, this inconsistency between vaccines and doses.
In older adults aged 18 to 64 years, IgG S1 concentrations were higher in other people with a history of SARS-CoV-2 after the first dose compared to others who had never received before, regardless of the type of vaccine. For others with a history of SARS-CoV-2 infection, no further increases occurred after a momentary dose, if any.
For Comirnaty, IgG grades were more heterogeneous in the older age group. However, these grades were not particularly different between older adults aged 18 to 64 years without prior infection (436 BAU/mL) and older adults aged 65 to 79 years (542 BAU/mL). mL) and ≥ 80 years (366 BAU/mL).
This has provided the most applicable confirmation of the effects of controlled trials of vaccines showing post-vaccination immunogenicity in the general population, adding vulnerable equipment and other vaccination schedules.
Although most people were seroconverted, regardless of the vaccine received, COVID-19 vaccines based on mRNA and vectors induced distinct S1-specific IgG kinetic patterns, and mRNA vaccines induced higher concentrations in the general population. More studies should be done to explore coverage. conferred against severe infection, as well as degrees of cell-mediated immunity induced by other vaccines.
medRxiv publishes initial clinical reports that are not peer-reviewed and therefore are not considered conclusive clinical practices/health-related behaviors, nor are they treated as established information.
Written by
Sreetama Dutt completed her B. Tech. in Biotechnology from SRM University in Chennai, India, and holds a Master’s degree in Medical Microbiology from the University of Manchester, UK. Initially, we decided to develop her career in laboratory research, medicine, writing and communication assaulted her when she least expected it. Of course, it’s not all coincidence.
Use one of the following to cite this article in your essay, article, or report:
ap
Dutt, Sreetama. (2021, November 02). A Dutchman compares mRNA vaccines with vector-based vaccines for COVID-19. Actus-Médicale. Retrieved November 12, 2022, from https://www. news-medical. net/news/20211102/Dutch–compares-mRNA-vaccines-to-vaccines-on-vector-for-COVID-19. aspx.
deputy
Dutt, Sreetama. ” Dutch compares mRNA vaccines to vector-based vaccines for COVID-19. “News-Medical. November 12, 2022.
Chicago
Dutt, Sreetama. ” Dutch compares mRNA vaccines to vector-based vaccines for COVID-19. “vector-based-vaccines-for-COVID-19. aspx. (accessed November 12, 2022).
Harvard
Dutt, Sreetama. 2021. Dutch compares mRNA vaccines with vector-based vaccines for COVID-19. News-Medical, accessed November 12, 2022, https://www. news-medical. net/news/20211102/Dutch–compares -mRNA-vaccines-to-vector-based-vaccines-for-COVID-19. aspx.
News-Medical. net – An AZoNetwork website
Owned and operated through AZoNetwork, © 2000-2022